IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Mariner LLC

Mariner LLC cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,072 shares of the medical research company's stock after selling 3,736 shares during the period. Mariner LLC's holdings in IQVIA were worth $2,765,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in IQV. Smith Group Asset Management LLC purchased a new stake in IQVIA during the fourth quarter worth $1,616,000. Nordea Investment Management AB grew its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after acquiring an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new position in shares of IQVIA in the 4th quarter valued at about $941,000. Fifth Third Bancorp raised its holdings in IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after purchasing an additional 1,521 shares during the period. Finally, Graphene Investments SAS grew its holdings in IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock valued at $2,948,000 after purchasing an additional 2,700 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IQV. Mizuho decreased their target price on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and dropped their target price for the company from $260.00 to $160.00 in a research report on Friday. JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Finally, Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $237.62.

IQVIA Trading Down 0.2 %

Shares of NYSE IQV traded down $0.30 during mid-day trading on Friday, reaching $150.38. 1,333,062 shares of the company's stock were exchanged, compared to its average volume of 1,420,529. The firm has a market capitalization of $26.51 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The company's 50-day moving average is $171.60 and its 200-day moving average is $194.05. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.